Literature review indicates antibiotics may restore chemotherapy sensitivity in treatment-resistant cancers — Evidence Review
Published in Cancer Biology & Medicine, by researchers from Nankai University, University of Utah, Tianjin Medical University Cancer Institute & Hospital
Researched by
— the AI search engine for science
Table of Contents
Some of the hardest-to-treat cancers may harbor bacteria that contribute to drug resistance, and a new review suggests combining antibiotics with chemotherapy could help, but most related research warns that antibiotic use often worsens cancer outcomes. Most existing studies find that antibiotics—especially when used broadly—can disrupt the microbiome and negatively impact cancer treatment response, raising concerns about applying this approach without further clinical evidence; see the full context from the study source.
- While the new review highlights the potential for antibiotics to restore treatment sensitivity in bacteria-infected tumors, most related studies show that antibiotics can disrupt the gut microbiome and impair the effectiveness of chemotherapy and immunotherapy, particularly immune checkpoint inhibitors, resulting in worse outcomes for cancer patients 1 2 3 5 11 12 13 14.
- Evidence from both animal and human studies strongly suggests that antibiotic-induced microbiome disruption can promote tumor growth, enhance chemoresistance, and reduce patient survival, especially in the context of immunotherapy and certain chemotherapies 2 3 5 12 13 14.
- Some literature recognizes the complexity of resistance mechanisms in cancer—beyond bacterial infection—including genetic, microenvironmental, and non-genetic adaptive processes, emphasizing the need for more precise, targeted approaches and caution in adopting widespread antibiotic use in oncology without robust clinical validation 6 7 8 9 10.
Study Overview and Key Findings
Many aggressive cancers, such as pancreatic and colorectal tumors, remain persistently resistant to treatment despite advances in chemotherapy and targeted therapies. This new review, published in Cancer Biology & Medicine, explores the possibility that bacteria residing within tumors contribute to this persistent resistance, and proposes that combining antibiotics with chemotherapy—without using nanocarriers—might help overcome this obstacle. The study is notable for challenging prevailing assumptions and suggesting a paradigm shift, while also acknowledging substantial gaps in direct clinical evidence and the challenges in reliably detecting intratumoral bacterial infections in patients.
Below is a summary of the study’s key details:
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Nankai University, University of Utah, Tianjin Medical University Cancer Institute & Hospital |
| Journal Name | Cancer Biology & Medicine |
| Authors | Henk J. Busscher, David W. Grainger, JinPu Yu, Da-Yuan Wang |
| Population | Poor prognosis outcome tumors |
| Methods | Literature Review |
| Outcome | Treatment resistance due to intratumoral bacteria |
| Results | Combining antibiotics with chemotherapy may restore treatment sensitivity. |
Literature Review: Related Studies
To place the new findings in context, we searched the Consensus paper database (over 200 million research papers) using targeted queries to capture the intersection of antibiotics, chemotherapy, and cancer treatment resistance. The following search queries were used:
- antibiotics chemotherapy cancer treatment sensitivity
- hidden factors cancer treatment resistance
- combination therapy cancer outcomes antibiotics
Summary Table of Related Topics and Key Findings
| Topic | Key Findings |
|---|---|
| How do antibiotics impact cancer treatment outcomes? | - Antibiotic use near chemotherapy or immunotherapy is consistently associated with worse clinical outcomes, including reduced survival and poorer treatment response 2 3 5 11 12 13 14. - Antibiotic-induced microbiome disruption can promote tumor growth, suppress immune response, and enhance resistance to chemotherapy in both animal models and human studies 1 3 5. |
| Can bacterial infections inside tumors drive treatment resistance? | - Intratumoral bacteria may contribute to chemotherapy resistance by metabolizing drugs and influencing the tumor microenvironment, though causation is difficult to establish and is just one of many resistance mechanisms 1 6 7 9. - The presence of certain bacterial species within tumors has been linked to local inflammation and altered immune activity, but more evidence is needed to confirm that bacterial infection is a primary driver of resistance in most cancers 1 6. |
| What are the risks and benefits of combining antibiotics with therapy? | - Some preclinical studies suggest that targeted antibiotic use may restore chemotherapy sensitivity in bacteria-infected tumor models, but clinical studies overwhelmingly indicate that broad or prophylactic antibiotic use often worsens patient outcomes 1 2 3 12 13 14. - The negative impact on survival is particularly pronounced when antibiotics are administered near the start of immune checkpoint inhibitor therapy, emphasizing the need for careful antibiotic stewardship 2 12 13 14. |
| What other mechanisms contribute to cancer drug resistance? | - Resistance to cancer therapy is multifactorial, involving genetic mutations, tumor heterogeneity, microenvironmental barriers, non-genetic adaptive mechanisms, and sometimes, microbial interactions 6 7 8 9 10. - Novel approaches such as early detection, adaptive monitoring, combination therapies, and precision immunotherapy are being explored to overcome drug resistance, but integrating antibiotics into this framework requires more targeted evidence 6 8 9 10. |
How do antibiotics impact cancer treatment outcomes?
Across multiple studies, antibiotic use—especially around the time of chemotherapy or immunotherapy—is consistently associated with poorer cancer outcomes, such as reduced progression-free survival, lower response rates, and shorter overall survival. These effects are largely attributed to disruption of the gut microbiome, which is increasingly recognized as an important modulator of immune function and treatment response in cancer patients.
- Antibiotic exposure prior to or during cancer therapy is linked with decreased treatment efficacy and survival in both lung cancer and ovarian cancer patients 2 3 5 11 12 13 14.
- Disruption of the gut microbiota by antibiotics can promote tumor progression and resistance to chemotherapy in animal models 3.
- The negative impact is especially pronounced for patients receiving immune checkpoint inhibitors, where microbiome diversity appears critical for optimal immune response 5 11 12 13 14.
- These findings suggest substantial risks associated with broad or prophylactic antibiotic use in oncology settings and underscore the need for antibiotic stewardship 2 14.
Can bacterial infections inside tumors drive treatment resistance?
The new review highlights the possibility that bacteria within tumors may directly contribute to resistance by inactivating drugs, modulating the microenvironment, or interfering with immune defenses. Related studies acknowledge this mechanism as plausible, but emphasize that many factors drive resistance, and causality remains unproven in most clinical contexts.
- Some bacteria (e.g., Fusobacterium nucleatum) have been found within tumors and may be linked to local inflammation and chemoresistance, but their direct role is still under investigation 1 6.
- Drug resistance is frequently multifactorial, with genetic, microenvironmental, and adaptive changes often playing a larger role than microbial presence alone 6 7 9.
- The presence of intratumoral bacteria does not always imply that they are the primary cause of resistance; more research is needed to clarify their contribution relative to other factors 1 6.
- Non-genetic and environmental mechanisms, in addition to microbial influence, are increasingly seen as important in therapy resistance 8.
What are the risks and benefits of combining antibiotics with therapy?
The reviewed study proposes that combining antibiotics with chemotherapy could help overcome resistance in bacteria-infected tumors. However, most clinical and meta-analytical research to date finds that antibiotic use—especially when not targeted—tends to worsen outcomes by undermining beneficial microbiota, especially in immunotherapy contexts.
- In animal tumor models, some combinations of antibiotics and chemotherapy (e.g., ciprofloxacin plus gemcitabine) have restored drug sensitivity, supporting further research into this approach 1.
- Multiple human studies and meta-analyses show that antibiotic use near the start of treatment often leads to reduced survival and worse responses, particularly for patients receiving immune checkpoint inhibitors 2 12 13 14.
- The negative effects are thought to result from microbiome disruption, which can impair immune surveillance and tumor suppression 3 5 11.
- Clinical use of antibiotics with chemotherapy should be evidence-based and carefully targeted, as broad use may do more harm than good 2 14.
What other mechanisms contribute to cancer drug resistance?
While bacteria may play a role in certain cases, the majority of research emphasizes that resistance to cancer therapies is complex and multifaceted, involving genetic mutations, tumor heterogeneity, microenvironmental barriers, and non-genetic adaptive responses. Emerging therapies aim to address these diverse mechanisms.
- Genetic alterations, epigenetic changes, and microenvironmental factors are major contributors to resistance across cancer types 6 7 9 10.
- Non-genetic adaptive mechanisms such as lineage switching and immune evasion are increasingly recognized in both experimental and clinical research 8.
- New strategies to overcome resistance include early detection, adaptive monitoring, novel drug development, and combination therapies tailored to individual tumor profiles 6 8 10.
- Integrating antibiotics into these strategies requires more robust, targeted evidence to avoid unintended negative effects 1 2 6 10.
Future Research Questions
Despite intriguing preclinical findings, substantial uncertainties remain regarding the role of intratumoral bacteria in cancer resistance and the potential for antibiotics to improve treatment outcomes. Future research should focus on clarifying when, how, and for whom antibiotic-chemotherapy combinations could be beneficial, while minimizing risks to the microbiome and avoiding antibiotic resistance.
| Research Question | Relevance |
|---|---|
| How can clinicians reliably detect and characterize bacterial infections inside tumors? | Accurate detection is crucial for targeted therapy; current clinical tests are limited, and treating without confirmation may harm beneficial microbes or promote resistance 1 3. |
| Does targeted antibiotic use improve chemotherapy outcomes in patients with bacteria-infected tumors? | While animal models show benefits, human studies mostly show harm from general antibiotic use; clinical trials focusing on targeted applications are needed to clarify efficacy and safety 1 2 3 12 13 14. |
| What are the long-term effects of antibiotic-induced microbiome disruption in cancer patients? | Microbiome disruption is linked to poor outcomes and increased resistance, but the long-term impacts and potential for recovery or intervention remain uncertain 3 5 11 12 13 14. |
| How do intratumoral bacteria alter the tumor microenvironment and drug delivery? | Mechanistic studies could reveal whether bacteria affect drug penetration, immune response, or resistance, informing more precise therapeutic strategies 1 6 8. |
| Can microbiome modifiers restore treatment sensitivity without harming beneficial bacteria? | Developing interventions (e.g., probiotics, targeted antibiotics) that restore sensitivity while preserving beneficial microbiota could improve patient outcomes and minimize risks 1 3 5 13. |